Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

399

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

August 6, 2021

Study Completion Date

October 29, 2021

Conditions
COVID-19Venous Thromboembolism
Interventions
DRUG

Dimolegin

60 mg orally, 1 time per day

DRUG

Clexane

40 mg subcutaneously, 1 time per day

Trial Locations (6)

150047

State budgetary institution of health care of the Yaroslavl region Yaroslavl Regional Clinical Hospital of War Veterans - International Center for the Problems of the Elderly Healthy Longevity, Yaroslavl

153025

Regional budgetary healthcare institution Ivanovskaya clinical hospital named after Kuvaevs, Ivanovo

197706

St. Petersburg State Budgetary Healthcare Institution City Hospital No. 40 of Kurortny District, Sestroretsk

350086

State Budgetary Institution of Healthcare Research Institute - Regional Clinical Hospital No. 1 named after Professor S.V. Ochapov Ministry of Health of the Krasnodar Territory, Krasnodar

390026

Federal State Budgetary Educational Institution of Higher Education Ryazan State Medical University named after academician I.P. Pavlova of the Ministry of Health of the Russian Federation, Ryazan

410028

State Healthcare Institution Saratov City Clinical Hospital No. 2 named after IN AND. Razumovsky, Saratov

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PharmaDiall Ltd.

OTHER